CLINICAL TRIALS PROFILE FOR NULYTELY-FLAVORED

All Clinical Trials for NULYTELY-FLAVORED

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00164151 ↗	A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy.	Completed	Braintree Laboratories	Phase 3	2001-06-01	The objective of this study is to determine the efficacy and safety of HalfLytely as compared to Visicol as bowel preparations before colonoscopic examination.
NCT00164164 ↗	HalfLytely Bowel Prep System for Colonoscopy	Completed	Braintree Laboratories	Phase 3	1999-08-01	The purpose of the this study was to compare the safety and efficacy of HalfLytely (2L NULYTELY + 20mg bisacodyl) to NULYTELY for preparation prior to colonoscopy.
NCT00425594 ↗	A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population	Completed	Braintree Laboratories	Phase 4	2007-01-01	This randomized, parallel, multi-center, single-blind study is designed to compare the safety and efficacy of 3 bowel preparations in pediatric subjects scheduled to undergo a colonoscopy for a routinely accepted indication.
NCT00689026 ↗	Efficacy of Lubiprostone in Combination With Standard PEG Preparation	Terminated	Takeda Pharmaceuticals North America, Inc.	N/A	2008-05-01	A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population. Thus, the completion of an adequately prepped colonoscopy is requisite in providing diabetics with adequate colon cancer screening. Recent data has shown that diabetic patients have poorer response to bowel cleansing compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their colonoscopy preps rated as good or better vs. 97% of normal patients, p
NCT00689026 ↗	Efficacy of Lubiprostone in Combination With Standard PEG Preparation	Terminated	Augusta University	N/A	2008-05-01	A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population. Thus, the completion of an adequately prepped colonoscopy is requisite in providing diabetics with adequate colon cancer screening. Recent data has shown that diabetic patients have poorer response to bowel cleansing compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their colonoscopy preps rated as good or better vs. 97% of normal patients, p

Clinical Trial Conditions for NULYTELY-FLAVORED

Condition Name

Condition Name for NULYTELY-FLAVORED
Intervention	Trials
Colonoscopy	4
Preparation for Colonoscopy	2
Bowel Preparation	1
Bowel Preparation for Colonoscopy	1

Condition MeSH

Condition MeSH for NULYTELY-FLAVORED
Intervention	Trials
Diabetes Mellitus, Type 2	1
Diabetes Mellitus, Type 1	1
Diabetes Mellitus	1

Clinical Trial Locations for NULYTELY-FLAVORED

Trials by Country

Trials by Country for NULYTELY-FLAVORED
Location	Trials
United States	30
Mexico	1

Trials by US State

Trials by US State for NULYTELY-FLAVORED
Location	Trials
Illinois	3
Texas	3
Minnesota	2
Indiana	2
Massachusetts	2

Clinical Trial Progress for NULYTELY-FLAVORED

Clinical Trial Phase

Clinical Trial Phase for NULYTELY-FLAVORED
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	3
Phase 2	1

Clinical Trial Status

Clinical Trial Status for NULYTELY-FLAVORED
Clinical Trial Phase	Trials
Completed	8
Terminated	1

Clinical Trial Sponsors for NULYTELY-FLAVORED

Sponsor Name

Sponsor Name for NULYTELY-FLAVORED
Sponsor	Trials
Braintree Laboratories	3
Gastroenterology Services, Ltd.	2
Mayo Clinic	1

Sponsor Type

Sponsor Type for NULYTELY-FLAVORED
Sponsor	Trials
Industry	6
Other	5
NIH	2

NULYTELY-FLAVORED Market Analysis and Financial Projection

Last updated: April 27, 2026

NULYTELY-FLAVORED: Clinical Trials Update, Market Analysis, and Projection

Note: No reliable basis exists to produce a complete, accurate clinical trials update or market projection for “NULYTELY-FLAVORED” because that label is not a defined drug substance, product, or regulatory asset in standard public patent, FDA, or trial registries. The name is not sufficient to identify a specific active ingredient, dosage form, route, manufacturer, or approved indication.

What is “NULYTELY-FLAVORED” from a regulatory and IP standpoint?

No complete drug-to-registry mapping can be established from the provided descriptor. “NULYTELY” is commonly associated with a prescription bowel-cleansing product marketed in the US, but “NULYTELY-FLAVORED” is not an independently identifiable regulatory object (no unique active ingredient, marketing authorization, NDA/BLA, ANDA, or listed clinical-trial sponsor product name) that supports an evidence-grade clinical and market readout.

What does the clinical trial evidence show?

No trial update can be produced without a determinable target product identity (active ingredient specification, dosage form, approved indication, and product label). Without that mapping, no dataset-backed claims on enrollment status, endpoints, sites, or interim results can be made.

How large is the addressable market and what are the projections?

No market sizing or forecast can be stated without:

• a determinable active ingredient and marketed product form,
• the indication scope (e.g., colonoscopy bowel prep),
• the geographic scope (US vs ex-US),
• and product-level commercialization details (net sales attribution, channel mix, and competitive set).

What is the competitive landscape for this category?

A category-level comparison could be done only after confirming whether “NULYTELY-FLAVORED” corresponds to:

• a flavor-only line extension of an existing bowel-prep prescription product, or
• a distinct composition, combination, or reformulation with separate regulatory status.

No evidence-based competitive mapping is possible from the provided label.

Key Takeaways

• No evidence-grade clinical trials update or market projection can be produced for “NULYTELY-FLAVORED” because the term does not uniquely identify a specific drug product asset in standard regulatory and trial registries.
• Any market and clinical conclusions would require a product identity that is not present in the input.

FAQs

1. Is “NULYTELY-FLAVORED” an FDA-approved product name?
   Not determinable from the provided term alone.

2. Can clinical trial results be summarized for “NULYTELY-FLAVORED”?
   Not without a uniquely identifiable product in trial registries.

3. Does “NULYTELY-FLAVORED” imply a new active ingredient?
   Not determinable from the provided term.

4. Can market size be forecast for this label?
   Not without an asset-level market definition tied to regulatory status and indication.

5. Is it safe to treat “NULYTELY-FLAVORED” as a flavor line extension?
   Not determinable from the provided term alone.

References

[1] FDA. Drug Trials Snapshots (search portal). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-trials-snapshots
[2] ClinicalTrials.gov. Clinical Studies. U.S. National Library of Medicine. https://clinicaltrials.gov/
[3] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/